Addex Therapeutics (NASDAQ:ADXN – Get Free Report) and Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Volatility & Risk
Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Profitability
This table compares Addex Therapeutics and Eton Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Addex Therapeutics | N/A | -134.76% | -106.00% |
| Eton Pharmaceuticals | 12.02% | 40.13% | 12.37% |
Institutional and Insider Ownership
Analyst Recommendations
This is a summary of current ratings and recommmendations for Addex Therapeutics and Eton Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Addex Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Eton Pharmaceuticals | 2 | 0 | 4 | 0 | 2.33 |
Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 8.36%. Given Eton Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Addex Therapeutics.
Valuation and Earnings
This table compares Addex Therapeutics and Eton Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Addex Therapeutics | $29,972.00 | 196.07 | -$8.12 million | ($5.94) | -0.80 |
| Eton Pharmaceuticals | $105.59 million | 16.86 | -$4.60 million | $0.38 | 163.92 |
Eton Pharmaceuticals has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eton Pharmaceuticals beats Addex Therapeutics on 12 of the 14 factors compared between the two stocks.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
